Safety and immunogenicity of COVAC-2, a Sepivac SWE™ adjuvanted SARS-CoV-2 recombinant protein vaccine in healthy adults; a randomized controlled first-in-human dose-escalation trial.

Safety and immunogenicity of COVAC-2, a Sepivac SWE™ adjuvanted SARS-CoV-2 recombinant protein vaccine in healthy adults; a randomized controlled first-in-human dose-escalation trial.

Publication date: Sep 15, 2025

Concepts Keywords
100g Clinical trial
54years COVID-19 vaccine
Headaches Immunogenicity
Oil Phase 1
Vaccine Protein subunit
SWE adjuvant
Vaccine

Semantics

Type Source Name
disease IDO protein
drug DRUGBANK Water
disease IDO site
disease MESH infection
disease MESH Seroconversion
disease IDO cell
disease IDO blood

Original Article

(Visited 6 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *